drugset
Drugs / ARC-520
last change Jan 2017 re-read 2 minutes ago

ARC-520

also known as ARC-520 Injection
Developed for
chronic hepatitis B virus infection · hepatitis B virus infection · hepatitis D virus infection
Investigated by
Arrowhead Pharmaceuticals · ICON Clinical Research

Trials 9 · a red edge is where a trial was stopped

today NCT02738008 · Ph 2 NCT02577029 · Ph 2 NCT02604212 · Ph 2 NCT02604199 · Ph 2 NCT02535416 · Ph 1 NCT02452528 · Ph 2 NCT02349126 · Ph 2 NCT02065336 · Ph 2 NCT01872065 · Ph 1
20142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT02535416 Sep 2015 → Aug 2016 — Arrowhead Pharmaceuticals Completed No outcome recorded
Phase 1 NCT01872065 Jul 2013 → Sep 2014 — Arrowhead Pharmaceuticals Completed No outcome recorded
Phase 27 trials
Phase 2 NCT02738008 Mar → Dec 2016 hepatitis B virus infection Arrowhead Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT02577029 Dec 2015 → Dec 2016 hepatitis B virus infection, hepatitis D virus infection Arrowhead Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT02604212 Nov 2015 → Dec 2016 hepatitis B virus infection Arrowhead Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT02604199 Sep 2015 → Jan 2017 chronic hepatitis B virus infection Arrowhead Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT02452528 Aug 2015 → Dec 2016 chronic hepatitis B virus infection Arrowhead Pharmaceuticals Terminated No outcome recorded
Phase 2 NCT02349126 Feb → Dec 2015 chronic hepatitis B virus infection Arrowhead Pharmaceuticals Withdrawn No outcome recorded
Phase 2 NCT02065336 Mar 2014 → Jan 2017 chronic hepatitis B virus infection Arrowhead Pharmaceuticals Terminated No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as ARC-520 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02577029 ↗
8

NCT02065336 ↗

NCT02452528 ↗

NCT02349126 ↗

NCT01872065 ↗

NCT02604199 ↗

NCT02535416 ↗

NCT02604212 ↗

NCT02738008 ↗
Known as ARC-520 Injection “ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.” NCT02349126 ↗
Action Inhibit “Treatment with ARC-520 for injection is expected to reduce all HBV proteins and replicative intermediates via ribonucleic acid (RNA) interference.” NCT02065336 ↗
Route Intravenous “Single dose, intravenous administration of ARC-520.” NCT01872065 ↗